Jayanth Doss
YOU?
Author Swipe
View article: A NOVEL MODELING APPROACH TO ELUCIDATE THE ROLE OF AUTOANTIBODIES IN COMPLEMENT ACTIVATION IN SLE
A NOVEL MODELING APPROACH TO ELUCIDATE THE ROLE OF AUTOANTIBODIES IN COMPLEMENT ACTIVATION IN SLE Open
PV228 / #365 Poster Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes Background/Purpose In SLE, autoantibodies (ANAs) can promote pathogenesis by forming immune complexes (ICs) that activate complement. While antibodies to DNA (anti…
View article: SOCIAL DRIVERS OF HEALTH IN A LARGE ACADEMIC LUPUS CLINIC
SOCIAL DRIVERS OF HEALTH IN A LARGE ACADEMIC LUPUS CLINIC Open
PV097a / #117 Poster Topic: AS11 - Epidemiology and Public Health Background/Purpose Adverse social drivers of health (SDoH) in systemic lupus erythematosus (SLE) are associated with worse health outcomes and quality of life. The aim of th…
View article: CHARACTERISTICS OF PATIENTS WITH INTERMITTENT AND PERSISTENT TYPE 2 SLE
CHARACTERISTICS OF PATIENTS WITH INTERMITTENT AND PERSISTENT TYPE 2 SLE Open
PV207 / #177 Poster Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes Background/Purpose Our prior qualitative work demonstrated there are at least 2 distinct subgroups of Type 2 SLE; one is related to active inflammation (Intermitte…
View article: THE ASSOCIATION BETWEEN TRAUMA AND QUALITY OF LIFE IN SLE.
THE ASSOCIATION BETWEEN TRAUMA AND QUALITY OF LIFE IN SLE. Open
PV233 / #350 Poster Topic: AS23 - SLE-Diagnosis, Manifestations, & Outcomes Background/Purpose In SLE, early childhood trauma and adverse childhood experiences have been associated with chronic pain, fatigue, depression, self-reported flar…
View article: Abstract 1990 Creating a Heparin-Binding, Hyper-Stable FGF1: Effects of a Targeted Two Mutation on the N-Terminus of Super FGF1
Abstract 1990 Creating a Heparin-Binding, Hyper-Stable FGF1: Effects of a Targeted Two Mutation on the N-Terminus of Super FGF1 Open
View article: Relationship between hydroxychloroquine blood levels and lupus activity through the lens of the type 1 and type 2 lupus model: a cross-sectional study
Relationship between hydroxychloroquine blood levels and lupus activity through the lens of the type 1 and type 2 lupus model: a cross-sectional study Open
Introduction In the type 1 and 2 SLE model, inflammation mediates type 1 manifestations, but its role in type 2 manifestations (eg, fatigue, myalgias, mood disturbance, cognitive dysfunction) is less clear. Therapeutic hydroxychloroquine (…
View article: Perspectives of Rheumatologists on the Type 1 and 2 Systemic Lupus Erythematosus Model
Perspectives of Rheumatologists on the Type 1 and 2 Systemic Lupus Erythematosus Model Open
Objective The Type 1 and 2 systemic lupus erythematosus (SLE) Model was developed to encapsulate all signs and symptoms that patients with SLE experience. Our previous qualitative work demonstrated the model accurately reflects the lived e…
View article: 303 Clinical and laboratory associations of longitudinal cell-bound complement activation products in SLE
303 Clinical and laboratory associations of longitudinal cell-bound complement activation products in SLE Open
Introduction Cell-bound complement activation products (CB-CAPs) in a multi-analyte assay with algorithm (MAP) is a valuable biomarker for the diagnosis of SLE. Erythrocyte-bound complement activation products have been associated with SLE…
View article: 605 Patterns of type 1 & type 2 systemic lupus erythematosus activity
605 Patterns of type 1 & type 2 systemic lupus erythematosus activity Open
Disclosures AME, JLR, MEBC: Exagen, Immunovant Funding Duke CTSA grant (UL1TR002553) Background The Type 1 & 2 SLE Model encompass symptoms classically attributed to inflammation, including arthritis, rash, serositis and neph…
View article: 107 Clinician-led intervention to improve medication adherence among patients with SLE
107 Clinician-led intervention to improve medication adherence among patients with SLE Open
Background Medication nonadherence is common and is associated with increased disease activity, morbidity, and mortality in SLE. Medication nonadherence is more common among patients from racial and ethnic minority groups, which likely con…
View article: Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study
Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study Open
Objective Characterise the relationship between hydroxychloroquine (HCQ) blood levels and the number of missed doses, accounting for dosage, dose timing and the large variability in pharmacokinetics (PK) between patients. Methods We extern…
View article: The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus
The Type 1 & 2 systemic lupus erythematosus model: Perspectives of people living with systemic lupus erythematosus Open
Objective In the new Type 1 & 2 model for systemic lupus erythematosus (SLE), Type 1 SLE represents classic inflammatory manifestations, such as arthritis, while Type 2 SLE encompasses symptoms such as pain and fatigue where the relationsh…
View article: A qualitative study of facilitators of medication adherence in systemic lupus erythematosus: Perspectives from rheumatology providers/staff and patients
A qualitative study of facilitators of medication adherence in systemic lupus erythematosus: Perspectives from rheumatology providers/staff and patients Open
Objective Systemic lupus erythematosus (SLE) disproportionately affects patients from racial and ethnic minority groups. Medication adherence is lower among these patient populations, and nonadherence is associated with worse health outcom…
View article: Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study
Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study Open
View article: Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study
Patient and Physician Perspectives of Systemic Lupus Erythematosus Flare: A Qualitative Study Open
Objective Systemic lupus erythematosus (SLE) flares are associated with increased damage and decreased health-related quality of life. We hypothesized that there is discordance between physicians’ and patients’ views of SLE flare. In this …
View article: Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms
Development and psychometric evaluation of a physician global assessment for type 2 systemic lupus erythematosus symptoms Open
Objective Manifestations of SLE can be categorised as type 1 (classic signs and symptoms of SLE) or type 2 (fatigue, widespread pain and brain fog with an unclear relationship to inflammation). While measures of type 1 SLE activity exist, …
View article: LSO-020 Intervention to improve medication adherence among patients with systemic lupus erythematosus
LSO-020 Intervention to improve medication adherence among patients with systemic lupus erythematosus Open
Background To optimize medication adherence and outcomes of patients with systemic lupus erythematosus (SLE), we developed an adherence intervention that encourages providers to review real-time pharmacy refill data and use effective commu…
View article: Development and Initial Validation of a Systemic Lupus Erythematosus–Specific Measure of the Extent of and Reasons for Medication Nonadherence
Development and Initial Validation of a Systemic Lupus Erythematosus–Specific Measure of the Extent of and Reasons for Medication Nonadherence Open
View article: 1803 The clinical characteristics of SLE patients with increased levels of cell-bound complement activation products
1803 The clinical characteristics of SLE patients with increased levels of cell-bound complement activation products Open
Background Cell-bound complement activation products (CB-CAPs), including erythrocyte-bound C4d (EC4d) and B-lymphocyte-bound C4d (BC4d), in a multi-analyte assay with algorithm (MAP) represent an important addition to the diagnostic armam…
View article: 616 Lower hydroxychloroquine blood levels are associated with higher Type 1 and 2 lupus activities
616 Lower hydroxychloroquine blood levels are associated with higher Type 1 and 2 lupus activities Open
Background Hydroxychloroquine (HCQ) is a mainstay of the initial and long-term treatment of systemic lupus erythematosus (SLE). HCQ blood levels can reflect adherence to the medication and have been correlated with SLE outcomes. However, l…
View article: 615 A pilot study to implement the Type 1 & 2 SLE Model into clinical care
615 A pilot study to implement the Type 1 & 2 SLE Model into clinical care Open
Background The Type 1 & 2 SLE Model was developed to better explain the signs, symptoms, and management goals of systemic lupus erythematosus (SLE) to patients. We assembled tools to discuss the Type 1 & 2 SLE Model, collectively called SL…
View article: Association of Hurried Communication and Low Patient <scp>Self‐Efficacy</scp> With Persistent Nonadherence to Lupus Medications
Association of Hurried Communication and Low Patient <span>Self‐Efficacy</span> With Persistent Nonadherence to Lupus Medications Open
Objective Medication nonadherence is common among patients with systemic lupus erythematosus (SLE), and adherence often fluctuates with time. Underrepresented racial minorities have disproportionately lower rates of medication adherence an…
View article: Development and Initial Validation of a Systemic Lupus Erythematosus–Specific Measure of the Extent of and Reasons for Medication Nonadherence
Development and Initial Validation of a Systemic Lupus Erythematosus–Specific Measure of the Extent of and Reasons for Medication Nonadherence Open
Objective Medication nonadherence is common in patients with systemic lupus erythematosus (SLE) and negatively affects outcomes. To better recognize and address nonadherence in this population, there is a need for an easily implementable t…
View article: Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms Open
Objective We have developed a new conceptual model to characterise the signs and symptoms of SLE: the Type 1 and 2 SLE Model. Within the original model, Type 1 SLE consists of inflammatory manifestations like arthritis, nephritis and rashe…
View article: Telehealth Made <scp>EASY</scp>: Understanding Provider Perceptions of Telehealth Appropriateness in Outpatient Rheumatology Encounters
Telehealth Made <span>EASY</span>: Understanding Provider Perceptions of Telehealth Appropriateness in Outpatient Rheumatology Encounters Open
Objective The purpose of this study was to evaluate a novel scoring system, the Encounter Appropriateness Score for You (EASY), to assess provider perceptions of telehealth appropriateness in rheumatology encounters. Methods The EASY scori…
View article: The use of patient-reported outcome measures to classify type 1 and 2 systemic lupus erythematosus activity
The use of patient-reported outcome measures to classify type 1 and 2 systemic lupus erythematosus activity Open
Objective We developed a model that categorizes systemic lupus erythematosus (SLE) activity into two dimensions: Type 1 SLE consists of inflammatory activity, including arthritis, nephritis, and rashes; Type 2 SLE includes fatigue, myalgia…
View article: Pilot Intervention to Improve Medication Adherence Among Patients With Systemic Lupus Erythematosus Using Pharmacy Refill Data
Pilot Intervention to Improve Medication Adherence Among Patients With Systemic Lupus Erythematosus Using Pharmacy Refill Data Open
Objective Despite high rates of medication nonadherence among patients with systemic lupus erythematosus (SLE), effective interventions to improve adherence in SLE are limited. We aimed to assess the feasibility of a pilot intervention and…
View article: 1001 Longitudinal changes in type 2 SLE activity
1001 Longitudinal changes in type 2 SLE activity Open
Background The Type 1 & 2 SLE Model categorizes signs and symptoms as Type 1 (arthritis, nephritis, and rash) and Type 2 (fatigue, brain fog, and widespread pain). It is currently unknown whether Type 2 SLE symptoms vary over time. In this…
View article: 1109 Clinical and laboratory manifestations of SLE patients with elevated cell-bound complement activation products
1109 Clinical and laboratory manifestations of SLE patients with elevated cell-bound complement activation products Open
Background Cell-bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte-bound C4d (BC4d) can be used as diagnostic tools in SLE; however, the clinical phenotype of patients with elevated CB-CA…
View article: 1115 The type 1 & 2 SLE model: the perspective of patients and rheumatologists
1115 The type 1 & 2 SLE model: the perspective of patients and rheumatologists Open
Background We have proposed a new model that divides SLE manifestations into Type 1 (objective signs of inflammation) and Type 2 (generalized pain and fatigue not clearly due to inflammation). We sought the opinions of patients and rheumat…